CSS
EGRX

Cubist Systematic Strategies’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Cubist Systematic Strategies’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6,152
Closed -$22.9K – 3705
2024
Q3 		$22.9K Sell
6,152
-19,660
-76% -$93.8K ﹤0.01% 2810
2024
Q2 		$145K Buy
+25,812
New +$112K ﹤0.01% 2572
2024
Q1 		– Sell
-15,228
Closed -$79.6K – 4398
2023
Q4 		$79.6K Sell
15,228
-43,303
-74% -$428K ﹤0.01% 3215
2023
Q3 		$923K Sell
58,531
-15,977
-21% -$287K 0.01% 1931
2023
Q2 		$1.45M Buy
74,508
+36,440
+96% +$864K 0.01% 1731
2023
Q1 		$1.08M Buy
38,068
+31,881
+515% +$946K 0.01% 2123
2022
Q4 		$181K Buy
+6,187
New +$197K ﹤0.01% 3628
2022
Q3 		– Sell
-9,658
Closed -$429K – 4825
2022
Q2 		$429K Sell
9,658
-3,021
-24% -$139K ﹤0.01% 3177
2022
Q1 		$627K Buy
12,679
+4,356
+52% +$209K 0.01% 2388
2021
Q4 		$424K Sell
8,323
-4,357
-34% -$226K ﹤0.01% 2568
2021
Q3 		$707K Buy
12,680
+4,346
+52% +$214K 0.01% 1788
2021
Q2 		$357K Sell
8,334
-7,667
-48% -$316K ﹤0.01% 2226
2021
Q1 		$668K Buy
16,001
+7,401
+86% +$344K 0.01% 1793
2020
Q4 		$401K Buy
8,600
+2,734
+47% +$128K 0.01% 1896
2020
Q3 		$249K Buy
+5,866
New +$257K ﹤0.01% 2047
2020
Q2 		– Sell
-5,463
Closed -$251K – 2558
2020
Q1 		$251K Buy
+5,463
New +$274K 0.01% 1607
2019
Q4 		– Sell
-5,862
Closed -$332K – 2581
2019
Q3 		$332K Sell
5,862
-2,815
-32% -$158K 0.01% 1507
2019
Q2 		$483K Buy
8,677
+214
+3% +$11.2K 0.01% 1494
2019
Q1 		$427K Sell
8,463
-15,043
-64% -$669K 0.01% 1288
2018
Q4 		$947K Buy
+23,506
New +$1.21M 0.04% 585
2017
Q4 		– Sell
-6,554
Closed -$391K – 2136
2017
Q3 		$391K Buy
6,554
+2,852
+77% +$173K 0.02% 980
2017
Q2 		$292K Buy
+3,702
New +$303K 0.02% 1054
2016
Q2 		– Sell
-1,378
Closed -$56K – 1921
2016
Q1 		$56K Buy
+1,378
New +$87.4K ﹤0.01% 1466
2015
Q4 		– Sell
-3,962
Closed -$293K – 1981
2015
Q3 		$293K Buy
3,962
+344
+10% +$28.6K 0.01% 1243
2015
Q2 		$293K Sell
3,618
-22,354
-86% -$1.46M 0.01% 1234
2015
Q1 		$1.09M Buy
+25,972
New +$737K 0.05% 526

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Cubist Systematic Strategies's EGRX Position: Q4 2024 in Review

Cubist Systematic Strategies sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 6,152 shares — an estimated $22.9K sold.

Cubist Systematic Strategies first reported a position in EGRX in Q1 2015 and held it in 26 quarters. The position peaked at $1.45M in Q2 2023. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • Cubist Systematic Strategies reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 6,152 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $22.9K.
  • Cubist Systematic Strategies first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and held it in 26 quarters.
  • Cubist Systematic Strategies's Eagle Pharmaceuticals, Inc. position peaked at $1.45M in Q2 2023.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Cubist Systematic Strategies's 13F filing for Q4 2024, filed 14 Feb 2025.